ArticleBlood cancer journal2024

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Maximilian Merz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.